Market research
XTLB XTL Biopharmaceuticals Ltd ADR
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 0.46
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US98386D4060
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 0.46
About
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the XTLB discussion.
5 years, 4 months ago
XTL Biopharmaceuticals Ltd is currently in a long term uptrend where the price is trading 16.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
XTL Biopharmaceuticals Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 118.5% to $205K since the same quarter in the previous year.
Based on the above factors, XTL Biopharmaceuticals Ltd gets an overall score of 3/5.